119 related articles for article (PubMed ID: 35979647)
21. Correlation between TRAIL and caspase-8 expression and their relationship with cell proliferation and apoptosis in human osteosarcoma.
Ning X; Shang XW; Zhuang Y; Liu M; Yang H; Zhang H; Huang MZ
Genet Mol Res; 2016 Dec; 15(4):. PubMed ID: 28002586
[TBL] [Abstract][Full Text] [Related]
22. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
[TBL] [Abstract][Full Text] [Related]
23. Simultaneously targeting Bcl-2 and Akt pathways reverses resistance of nasopharyngeal carcinoma to TRAIL synergistically.
Li SS; Tang QL; Wang SH; Chen YH; Liu JJ; Yang XM
Tumori; 2011; 97(6):762-70. PubMed ID: 22322844
[TBL] [Abstract][Full Text] [Related]
24. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
Izeradjene K; Douglas L; Delaney A; Houghton JA
Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential.
Hotta T; Suzuki H; Nagai S; Yamamoto K; Imakiire A; Takada E; Itoh M; Mizuguchi J
J Orthop Res; 2003 Sep; 21(5):949-57. PubMed ID: 12919886
[TBL] [Abstract][Full Text] [Related]
26. Synergistic effect of celecoxib in tumor necrosis factor‑related apoptosis‑inducing ligand treatment in osteosarcoma cells.
Liu G; Yu MY; Huang X; Zhu D; Cheng S; Ma R; Gu G
Mol Med Rep; 2014 Oct; 10(4):2198-202. PubMed ID: 25050836
[TBL] [Abstract][Full Text] [Related]
27. X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO).
Ng CP; Bonavida B
Mol Cancer Ther; 2002 Oct; 1(12):1051-8. PubMed ID: 12481428
[TBL] [Abstract][Full Text] [Related]
28. Proteasome inhibitor MG132 enhances TRAIL-induced apoptosis and inhibits invasion of human osteosarcoma OS732 cells.
Li X; Huang T; Jiang G; Gong W; Qian H; Zou C
Biochem Biophys Res Commun; 2013 Sep; 439(2):179-86. PubMed ID: 23994633
[TBL] [Abstract][Full Text] [Related]
29. Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells.
Wang X; Chen W; Zeng W; Bai L; Tesfaigzi Y; Belinsky SA; Lin Y
Mol Cancer Ther; 2008 May; 7(5):1156-63. PubMed ID: 18483303
[TBL] [Abstract][Full Text] [Related]
30. Evodiamine sensitizes U87 glioblastoma cells to TRAIL via the death receptor pathway.
Khan M; Bi Y; Qazi JI; Fan L; Gao H
Mol Med Rep; 2015 Jan; 11(1):257-62. PubMed ID: 25333675
[TBL] [Abstract][Full Text] [Related]
31. Role of antiapoptotic proteins in tumor necrosis factor-related apoptosis-inducing ligand and cisplatin-augmented apoptosis.
Kim JH; Ajaz M; Lokshin A; Lee YJ
Clin Cancer Res; 2003 Aug; 9(8):3134-41. PubMed ID: 12912965
[TBL] [Abstract][Full Text] [Related]
32. Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells.
Weng C; Li Y; Xu D; Shi Y; Tang H
J Biol Chem; 2005 Mar; 280(11):10491-500. PubMed ID: 15637055
[TBL] [Abstract][Full Text] [Related]
33. Apigenin induces apoptosis via tumor necrosis factor receptor- and Bcl-2-mediated pathway and enhances susceptibility of head and neck squamous cell carcinoma to 5-fluorouracil and cisplatin.
Chan LP; Chou TH; Ding HY; Chen PR; Chiang FY; Kuo PL; Liang CH
Biochim Biophys Acta; 2012 Jul; 1820(7):1081-91. PubMed ID: 22554915
[TBL] [Abstract][Full Text] [Related]
34. The secreted protein acidic and rich in cysteine is a critical mediator of cell death program induced by WIN/TRAIL combined treatment in osteosarcoma cells.
Notaro A; Sabella S; Pellerito O; Vento R; Calvaruso G; Giuliano M
Int J Oncol; 2016 Mar; 48(3):1039-44. PubMed ID: 26698404
[TBL] [Abstract][Full Text] [Related]
35. Myricetin sensitizes malignant glioma cells to TRAIL-mediated apoptosis by down-regulation of the short isoform of FLIP and bcl-2.
Siegelin MD; Gaiser T; Habel A; Siegelin Y
Cancer Lett; 2009 Oct; 283(2):230-8. PubMed ID: 19398149
[TBL] [Abstract][Full Text] [Related]
36. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
Ng CP; Zisman A; Bonavida B
Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140
[TBL] [Abstract][Full Text] [Related]
37. Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP.
Kang J; Bu J; Hao Y; Chen F
Prostate Cancer Prostatic Dis; 2005; 8(3):274-9. PubMed ID: 15897917
[TBL] [Abstract][Full Text] [Related]
38. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells.
Guo F; Sigua C; Tao J; Bali P; George P; Li Y; Wittmann S; Moscinski L; Atadja P; Bhalla K
Cancer Res; 2004 Apr; 64(7):2580-9. PubMed ID: 15059915
[TBL] [Abstract][Full Text] [Related]
39. Survivin inhibitor YM-155 sensitizes tumor necrosis factor- related apoptosis-inducing ligand-resistant glioma cells to apoptosis through Mcl-1 downregulation and by engaging the mitochondrial death pathway.
Premkumar DR; Jane EP; Foster KA; Pollack IF
J Pharmacol Exp Ther; 2013 Aug; 346(2):201-10. PubMed ID: 23740602
[TBL] [Abstract][Full Text] [Related]
40. Artepillin C (3,5-diprenyl-4-hydroxycinnamic acid) sensitizes LNCaP prostate cancer cells to TRAIL-induced apoptosis.
Szliszka E; Zydowicz G; Mizgala E; Krol W
Int J Oncol; 2012 Sep; 41(3):818-28. PubMed ID: 22735465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
